Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|March 23, 2016

Vetter Breaks Ground on New Production Facility

The company broke ground on a $79 million production facility at its Ravensburg Schuetzenstrasse site.

Vetter, a contract development and manufacturing organization (CDMO) for the development, commercial manufacturing, and final packaging of aseptically prefilled drug-delivery systems, announced the construction of a new building at a groundbreaking ceremony held at its Ravensburg Schuetzenstrasse site on March 22, 2016.

According to a press announcement, the new facility is scheduled for completion in the first quarter of 2018, the building is planned to begin operations in early 2019. Vetter says the new production facility is expected to cost approximately €70 million ($79 million) and is part of the total investment strategy announced by the company in September 2015.

Upon completion, the seven-story building will cover a total of 8000 square meters and include a cleanroom with supportive media systems. The applied technology of the cleanroom will be dedicated to the filling of bulk syringes and designed to be compatible for the filling of sensitive drugs such as biologics and opthalmics. Another central technological element of the cleanroom will be the implementation of an improved restricted access barrier system (RABS) concept to combine the advantages of isolator and RABS technology. The core of this innovative approach is a three-hour cycle and fully automated decontamination of the cleanroom using hydrogen peroxide (H2O2).

Source: Vetter


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.